Warm Autoimmune Hemolytic Anemia

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) lett...

Warm Autoimmune Hemolytic Anemia market is anticipated to increase with a CAGR of 15.9% in the 7MM by 2030, estimates DelveInsight. In 2017, as per the estimates by DelveInsight, Warm Autoimmune Haemolytic Anemia had affected 82,045 people approximately in the 7MM. For a disease being tagged - rare, WAIHA affect...